TheraRadar
Clinical-Stage Companies / Taiwan Liposome Company

Taiwan Liposome Company

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 4/1/2025

17
Total Trials
2
Phase 3
13
Phase 2
0
Recruiting
161
Score

Pipeline by Phase

Phase 3
2
Phase 2
13
Phase 1
9

Therapeutic Focus

Osteoarthritis of the Knee Postsurgical Pain Management Central Retinal Vein Occlusion With Macular Edema Branch Retinal Vein Occlusion With Macular Edema Retinal Vein Occlusion

Clinical Trials (17)

NCT04123561 Phase 3 COMPLETED

Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain

Started: 11/26/2019

NCT03754049 Phase 2 COMPLETED

A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee

Started: 1/21/2019

NCT03005873 Phase 2 COMPLETED

Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients

Started: 3/16/2017

NCT05161637 Phase 2 NOT YET RECRUITING

Phase 2/3 Study of TLC590 for Postsurgical Pain Management

Started: 4/1/2025

NCT03093701 Phase 2 COMPLETED

TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Started: 4/1/2017

NCT03838133 Phase 2 COMPLETED

A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

Started: 3/5/2019

NCT02267213 Phase 2 TERMINATED

Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

Started: 4/10/2014

NCT01831973 Phase 2 COMPLETED

A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients

Started: 11/30/2012

NCT02803307 Phase 1 COMPLETED

Single-Dose Administration Trial of TLC599 in Osteoarthritis of the Knee

Started: 6/1/2015

NCT02006147 Phase 1 COMPLETED

Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO

Started: 11/1/2014

NCT04697654 Phase 1 COMPLETED

The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers

Started: 10/8/2020

NCT02925000 Phase 1 COMPLETED

Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy

Started: 6/19/2017

NCT03591146 Phase 1 COMPLETED

Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management

Started: 7/31/2018

NCT00747474 Phase 1 COMPLETED

Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors

Started: 9/1/2008

NCT03035006 Phase 1 TERMINATED

Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Started: 4/14/2017

NCT01425996 Phase 1 TERMINATED

A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma

Started: 10/27/2011

NCT01652859 Phase 1 COMPLETED

An Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy Subjects

Started: 2/1/2012

Drug Candidates

TLC599 DSP TLC599 LD group Normal Saline TLC599 HD group TLC590 Bupivacain Ropivacaine Normal saline TLC399
Activity Status: Slowing
Last Trial Started: 4/1/2025
Last Trial Ended: 11/7/2023
Trials (12 months): 0
Completed Trials: 13
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.